Envision Pharma Group promotes Jennifer Lospinoso to President, Riparian

Market access and pricing specialist to lead Envision's value optimization business
4 minute read

Envision Pharma Group has promoted Jennifer (Jenn) Lospinoso to President of Riparian, its business unit focused on pricing, access, and value optimization for pharmaceutical and biotech companies.

Lospinoso, who came to Envision in 2022 as part of the acquisition of Riparian, will lead the business as it continues to support life sciences organizations working through increasingly complex market access, pricing, reimbursement, and regulatory environments.

She brings more than 20 years of experience across government and commercial program operations, strategy, and compliance, and is widely recognized for helping pharmaceutical manufacturers implement commercial strategies and navigate evolving regulatory and reimbursement requirements across government programs.

Tom Langan, CEO of Envision Pharma Group, says, “Jenn’s promotion reflects her exceptional leadership, deep industry expertise, and unwavering commitment to clients. Riparian represents a significant growth opportunity for Envision, and I’m confident that Jenn and her team will drive the innovation and excellence that sets us apart and delivers for our clients.”

Prior to Riparian, Lospinoso led government rebates, gross-to-net, and government contracting at a top five pharmaceutical company, and previously served as a Managing Director at a Big Four accounting firm, advising a broad range of life sciences organizations. She is a frequent industry speaker with more than 100 engagements covering cell and gene therapy strategies, Medicare, Medicaid, 340B, and US pricing models.

She will continue to report to Langan and serve on the Envision Executive Leadership Team. 

Lospinoso adds, “I am honored to lead the Riparian team. This group brings extraordinary depth of knowledge across market access, value strategy, competitive intelligence, and governmental and regulatory pricing and contracting, all amplified by our market-leading managed service offering and the AI technology we’ve built to support it. Together, these capabilities create tremendous potential, and I look forward to partnering with Tom and Envision’s Executive Leadership Team to accelerate what we can achieve.”

Author

Author name

Job role name

From the author

“Lorem ipsum dolor sit amet mas elitius geaiun garetein prouig mas qeuin”

Author

Author name

Job role name

News and views

Technology and AI focus drives dual hire across product and information technology...
Technology and life sciences leader to advance AI integration across medical communications...
Envision's strategic framework for sustainable transformation before, during, and after technology implementation...